Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Georgios Schoretsanitis, Jonathan M. Meyer, Andreas Conca & Christoph Hiemke. (2023) Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations. Expert Opinion on Drug Metabolism & Toxicology 19:4, pages 189-202.
Read now
Read now
Yun-Yun Zhan, Bing-Qing Liang, Xiang-Yu Li, Er-Min Gu, Da-Peng Dai, Jian-Ping Cai & Guo-Xin Hu. (2016) The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. Xenobiotica 46:5, pages 439-444.
Read now
Read now
Arash Raoufinia, Ross A. Baker, Anna Eramo, Anna-Greta Nylander, Wally Landsberg, Dusan Kostic & Frank Larsen. (2015) Initiation of aripiprazole once-monthly in patients with schizophrenia. Current Medical Research and Opinion 31:3, pages 583-592.
Read now
Read now
Silvio Caccia. (2011) Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opinion on Drug Metabolism & Toxicology 7:7, pages 829-846.
Read now
Read now
Gianluca Nucci, Roberto Gomeni & Italo Poggesi. (2009) Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity. Expert Opinion on Drug Discovery 4:8, pages 837-856.
Read now
Read now
Articles from other publishers (78)
Rachel E. Hardy, Injae Chung, Yizhou Yu, Samantha H. Y. Loh, Nobuhiro Morone, Clement Soleilhavoup, Marco Travaglio, Riccardo Serreli, Lia Panman, Kelvin Cain, Judy Hirst, Luis M. Martins, Marion MacFarlane & Kenneth R. Pryde. (2023) The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors. Biology Direct 18:1.
Crossref
Crossref
Karen Tangmose, Egill Rostrup, Kirsten Borup Bojesen, Anne Sigvard, Birte Y. Glenthøj & Mette Ødegaard Nielsen. (2023) Clinical response to treatment with a partial dopamine agonist is related to changes in reward processing. Psychiatry Research 326, pages 115308.
Crossref
Crossref
Jelena Z. Penjišević, Vladimir B. Šukalović, Sladjana Dukic-Stefanovic, Winnie Deuther-Conrad, Deana B. Andrić & Slađana V. Kostić-Rajačić. (2023) Synthesis of novel 5-HT1A arylpiperazine ligands: Binding data and computer-aided analysis of pharmacological potency. Arabian Journal of Chemistry 16:4, pages 104636.
Crossref
Crossref
Jens Borggaard Larsen, Elke Hoffmann-Lücke, Per Hersom Aaslo, Niklas Rye Jørgensen & Eva Greibe. (2023) Automated Interlaboratory Comparison of Therapeutic Drug Monitoring Data and Its Use for Evaluation of Published Therapeutic Reference Ranges. Pharmaceutics 15:2, pages 673.
Crossref
Crossref
Milica Vranic, Fozia Ahmed, Susanne Hetty, Assel Sarsenbayeva, Vitor Ferreira, Giovanni Fanni, Ángela M. Valverde, Jan W. Eriksson & Maria J. Pereira. (2023) Effects of the second-generation antipsychotic drugs aripiprazole and olanzapine on human adipocyte differentiation. Molecular and Cellular Endocrinology 561, pages 111828.
Crossref
Crossref
Zhizhong Xu, Chunyan Wen, Yinghua Huang, Qianfa Yuan, Xianhua Zhang, Duoduo Lin, Liangsheng Liu & Wenqiang Wang. (2022) Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of Molecular Neuroscience 73:1, pages 76-83.
Crossref
Crossref
Xenia M. Hart, Christoph Hiemke, Luzie Eichentopf, Xenija M. Lense, Hans Willi Clement, Andreas Conca, Frank Faltraco, Vincenzo Florio, Jessica Grüner, Ursula Havemann-Reinecke, Espen Molden, Michael Paulzen, Georgios Schoretsanitis, Thomas G. Riemer & Gerhard Gründer. (2022) Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis. Psychopharmacology 239:11, pages 3377-3391.
Crossref
Crossref
Shih-Ku Lin. (2022) Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on East Asians. Journal of Personalized Medicine 12:9, pages 1362.
Crossref
Crossref
Xiaofeng Wang, Arash Raoufinia, Sébastien Bihorel, Julie Passarell, Suresh MallikaarjunLuann Phillips. (2022) Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia. Clinical Pharmacology in Drug Development 11:2, pages 150-164.
Crossref
Crossref
Nicholus Warstadt, Sanjay Mohan, Emma Furlano, Jennifer Shenker, Eric Gibbs & Silas Smith. (2022) Abilifright: A Case Report of Massive Aripiprazole Overdose in a Toddler. Clinical Practice and Cases in Emergency Medicine 6:1, pages 44-48.
Crossref
Crossref
E. Raskin & M. Danckaerts. (2022) De impact van CYP2D6-polymorfisme op een behandeling met aripiprazol bij kinderen en jongeren: een systematische review. Tijdschrift voor Geneeskunde.
Crossref
Crossref
Gerald Zernig, Sabine Bischinger & Christoph Hiemke. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
361
414
.
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
833
864
.
Lisa Alina Kneller, Pablo Zubiaur, Dora Koller, Francisco Abad-Santos & Georg Hempel. (2021) Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. Clinical Pharmacokinetics 60:12, pages 1569-1582.
Crossref
Crossref
Ditte Rudå, Karsten Gjessing Jensen, Marie Stentebjerg Decara, Dea Gowers Klauber, Birgitte Fagerlund, Jens Richardt Møllegaard, Kristian Linnet, Thomas Werge, Christoph U. Correll, Anders Fink-Jensen, Gesche Jürgens & Anne Katrine Pagsberg. (2021) CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12–17 Years, With First Episode Psychosis. Journal of Clinical Psychopharmacology 41:6, pages 667-672.
Crossref
Crossref
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clinical Use of Antipsychotic Plasma Levels. The Clinical Use of Antipsychotic Plasma Levels
318
336
.
Ian R. McGrane, Tori J. Lindbloom & Robert C. Munjal. (2021) Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Mental Health Clinician 11:5, pages 297-300.
Crossref
Crossref
Shawn Herring, Jessica M. Oda, Jessica Wagoner, Delaney Kirchmeier, Aidan O’Connor, Elizabeth A. Nelson, Qinfeng Huang, Yuying Liang, Lisa Evans DeWald, Lisa M. Johansen, Pamela J. Glass, Gene G. Olinger, Aleksandr Ianevski, Tero Aittokallio, Mary F. Paine, Susan L. Fink, Judith M. White & Stephen J. Polyak. (2021) Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. Antimicrobial Agents and Chemotherapy 65:4.
Crossref
Crossref
Ping Jiang, Xiujia Sun, Juanjuan Ren, Hongmei Liu, Zhiguang Lin, Junwen Liu, Xinyu Fang & Chen Zhang. (2021) Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia. General Psychiatry 34:2, pages e100423.
Crossref
Crossref
Assel Sarsenbayeva, Priya Dipta, Martin Lundqvist, Kristina E. Almby, Boaz Tirosh, Giada Di Nunzio, Jan W. Eriksson & Maria J. Pereira. (2021) Human macrophages stimulate expression of inflammatory mediators in adipocytes; effects of second-generation antipsychotics and glucocorticoids on cellular cross-talk. Psychoneuroendocrinology 125, pages 105071.
Crossref
Crossref
Stefanie Fekete, K. Egberts, T. Preissler, C. Wewetzer, C. Mehler-Wex, M. Romanos & M. Gerlach. (2020) Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride. European Journal of Clinical Pharmacology 77:2, pages 163-170.
Crossref
Crossref
Beatriz Carvalho Henriques, Esther H. Yang, Diego Lapetina, Michael S. Carr, Vasyl Yavorskyy, Joshua Hague & Katherine J. Aitchison. (2020) How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. Frontiers in Genetics 11.
Crossref
Crossref
Karin Egberts, Su-Yin Reuter-Dang, Stefanie Fekete, Christine Kulpok, Claudia Mehler-Wex, Christoph Wewetzer, Andreas Karwautz, Michaela Mitterer, Kristian Holtkamp, Isabel Boege, Rainer Burger, Marcel Romanos, Manfred Gerlach & Regina Taurines. (2020) Therapeutic drug monitoring of children and adolescents treated with aripiprazole: observational results from routine patient care. Journal of Neural Transmission 127:12, pages 1663-1674.
Crossref
Crossref
Jeaneun Park, Kwang-Hyun Cho, Hong Joon Lee, Jin-Sung Choi & Duck-Joo Rhie. (2020) Open channel block of Kv1.4 potassium channels by aripiprazole. The Korean Journal of Physiology & Pharmacology 24:6, pages 545-553.
Crossref
Crossref
Gianni Parigi, Lucia Terzuoli, Arianna Goracci, Serena Piccione, Costanza Taddeucci, Marina Salvi, Carlo Scapellato & Brunetta Porcelli. (2020) Dosaggio dell’aripiprazolo totale: messa a punto del metodo su analizzatore Cobas® 8000. La Rivista Italiana della Medicina di Laboratorio 16:3.
Crossref
Crossref
Habibur Rahman, S.K. Manirul Haque & Masoom Raza Siddiqui. (2020) A Comprehensive Review on Importance and Quantitation of Atypical Antipsychotic Drugs and their Active Metabolites in Commercial Dosage Forms. Current Pharmaceutical Analysis 16:8, pages 989-1019.
Crossref
Crossref
Diego L. Lapetina, Esther H. Yang, Beatriz C. Henriques & Katherine J. Aitchison. 2020. Seminars in Clinical Psychopharmacology. Seminars in Clinical Psychopharmacology
151
202
.
Ádám Kiss, Ádám Menus, Katalin Tóth, Máté Déri, Dávid Sirok, Evelyn Gabri, Ales Belic, Gábor Csukly, István Bitter & Katalin Monostory. (2019) Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. European Archives of Psychiatry and Clinical Neuroscience 270:1, pages 71-82.
Crossref
Crossref
Yoshiaki Obayashi, Satoshi Mitsui, Shinji Sakamoto, Nozomu Minao, Bunta Yoshimura, Toshiki Kono, Yuji Yada, Yuko Okahisa, Soshi Takao, Yoshiki Kishi, Toshihiko Takeda, Manabu Takaki & Norihito Yamada. (2019) Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole. Psychopharmacology 237:1, pages 167-175.
Crossref
Crossref
Gerald Zernig, Sabine Bischinger & Christoph Hiemke. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
53
.
Assel Sarsenbayeva, Cátia M. Marques-Santos, Ketan Thombare, Giada Di Nunzio, Kristina E. Almby, Martin Lundqvist, Jan W. Eriksson & Maria J. Pereira. (2019) Effects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism. Psychoneuroendocrinology 110, pages 104445.
Crossref
Crossref
Muhammet Serhat Özaslan, Neslihan Balcı, Yeliz Demir, Mahmut Gürbüz & Ömer İrfan Küfrevioğlu. (2019) Inhibition effects of some antidepressant drugs on pentose phosphate pathway enzymes. Environmental Toxicology and Pharmacology 72, pages 103244.
Crossref
Crossref
Chiara Rapinesi, Georgios D. Kotzalidis, Lorenzo Mazzarini, Roberto Brugnoli, Stefano Ferracuti, Sergio De Filippis, Ilaria Cuomo, Gloria Giordano, Antonio Del Casale, Gloria Angeletti, Gabriele Sani & Paolo Girardi. (2019) Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review. Clinical Drug Investigation 39:8, pages 713-735.
Crossref
Crossref
László-István Bába, Melinda Kolcsár, Imre Zoltán Kun, Zsófia Ulakcsai, Fruzsina Bagaméry, Éva Szökő, Tamás Tábi & Zsolt Gáll. (2019) Effects of Cariprazine, Aripiprazole, and Olanzapine on Mouse Fibroblast Culture: Changes in Adiponectin Contents in Supernatants, Triglyceride Accumulation, and Peroxisome Proliferator-Activated Receptor-γ Expression. Medicina 55:5, pages 160.
Crossref
Crossref
Jochen Gehrmann & Peter Götz Lampe. (2019) Serum Level Measurements Optimize Aripriprazole Treatment in Adolescent Patients. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 47:3, pages 261-264.
Crossref
Crossref
Marin M Jukic, Robert L Smith, Tore Haslemo, Espen Molden & Magnus Ingelman-Sundberg. (2019) Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. The Lancet Psychiatry 6:5, pages 418-426.
Crossref
Crossref
Emma Tay, Andreas Sotiriou, Garry G. Graham, Kay Wilhelm, Leone Snowden & Richard O. Day. (2019) Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance. Therapeutic Advances in Psychopharmacology 9, pages 204512531983688.
Crossref
Crossref
Mohammad Raish, Ajaz Ahmad, Mushtaq Ahmad Ansari, Khalid M. Alkharfy, Abdul Ahad, Altaf Khan, Fahad I. Aljenobi, Naushad Ali & Abdullah M. Al-Mohizea. (2019) Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction. Journal of Food and Drug Analysis 27:1, pages 332-338.
Crossref
Crossref
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli & Alfredo Carlo Altamura. (2018) Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical Pharmacokinetics 57:12, pages 1493-1528.
Crossref
Crossref
Dora Koller, Carmen Belmonte, Rubin Lubomirov, Miriam Saiz-Rodríguez, Pablo Zubiaur, Manuel Román, Dolores Ochoa, Antonio Carcas, Aneta Wojnicz & Francisco Abad-Santos. (2018) Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. Journal of Psychopharmacology 32:11, pages 1212-1222.
Crossref
Crossref
Marjie L. Hard, Angela Y. Wehr, Yangchun Du, Peter J. Weiden, David Walling & Lisa von Moltke. (2018) Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia. Journal of Clinical Psychopharmacology 38:5, pages 435-441.
Crossref
Crossref
Ian R. McGrane, Joshua G. Loveland & Jose de Leon. (2017) Possible Oxcarbazepine Inductive Effects on Aripiprazole Metabolism: A Case Report. Journal of Pharmacy Practice 31:3, pages 361-363.
Crossref
Crossref
Sanne M. Kloosterboer, Brenda C. M. de WinterSoma BahmanyLinda Al-HassanyAnnet Dekker, Gwen C. DielemanTeun van GelderBram DierckxBirgit C. P. Koch. (2018) Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Antipsychotics: Drawbacks of Its Clinical Application. Therapeutic Drug Monitoring 40:3, pages 344-350.
Crossref
Crossref
Manabu Takaki, Masafumi Kodama, Yutaka Mizuki, Hiroki Kawai, Bunta Yoshimura, Makiko Kishimoto, Shinji Sakamoto, Yuko Okahisa & Norihito Yamada. (2018) Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine. European Neuropsychopharmacology 28:5, pages 610-619.
Crossref
Crossref
Austen B. Casey & Clinton E. Canal. (2017) Classics in Chemical Neuroscience: Aripiprazole. ACS Chemical Neuroscience 8:6, pages 1135-1146.
Crossref
Crossref
Stefanie Fekete, Christoph Wewetzer, Claudia Mehler-Wex, Kristian Holtkamp, Rainer Burger, Susanne Reichert, Regina Taurines, Marcel Romanos, Manfred Gerlach & Karin Egberts. (2017) Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice. Therapeutic Drug Monitoring 39:3, pages 273-281.
Crossref
Crossref
Arash Raoufinia, Timothy Peters-Strickland, Anna-Greta Nylander, Ross A. Baker, Anna Eramo, Na Jin, Patricia Bricmont, Jennifer Repella, Robert D. McQuade, Peter Hertel & Frank Larsen. (2017) Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. International Journal of Neuropsychopharmacology 20:4, pages 295-304.
Crossref
Crossref
Goyo Nagai, Kazuo Mihara, Akifumi Nakamura, Kenji Nemoto, Shoko Kagawa, Takeshi SuzukiTsuyoshi Kondo. (2017) Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1. Therapeutic Drug Monitoring 39:1, pages 62-65.
Crossref
Crossref
Martina Hahn & Sibylle C. Roll. (2016) Dosing Recommendations of Aripiprazole Depot with Strong Cytochrome P450 3A4 Inhibitors: A Relapse Risk. Drug Safety - Case Reports 3:1.
Crossref
Crossref
Lora Humphrey Beebe, Kathleen Smith & Chad Phillips. (2016) Descriptions and Correlates of Medication Adherence, Attitudes, and Self-Efficacy in Outpatients With Schizophrenia Spectrum Disorders (SSDs). Archives of Psychiatric Nursing 30:3, pages 400-405.
Crossref
Crossref
Andrea de Bartolomeis, Carmine Tomasetti & Felice Iasevoli. (2015) Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs 29:9, pages 773-799.
Crossref
Crossref
Karen van der Weide & Jan van der Weide. (2015) The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients. Journal of Clinical Psychopharmacology 35:3, pages 228-236.
Crossref
Crossref
N. Simon & J.-M. Azorin. (2015) Estimation rationnelle d’une posologie par modélisation pharmacométrique : application au cas d’un antipsychotique d’action prolongée. L'Encéphale 41:2, pages 159-167.
Crossref
Crossref
Louise Skov, Sys Stybe Johansen & Kristian Linnet. (2015) Postmortem Femoral Blood Reference Concentrations of Aripiprazole, Chlorprothixene, and Quetiapine. Journal of Analytical Toxicology 39:1, pages 41-44.
Crossref
Crossref
Akifumi Nakamura, Kazuo Mihara, Kenji Nemoto, Goyo Nagai, Shoko Kagawa, Takeshi Suzuki & Tsuyoshi Kondo. (2014) Lack of Correlation Between the Steady-State Plasma Concentrations of Aripiprazole and Haloperidol in Japanese Patients With Schizophrenia. Therapeutic Drug Monitoring 36:6, pages 815-818.
Crossref
Crossref
Elmar Windhager, Sung-Wan Kim, Alois Saria, Katharina Zauner, Paul G. Amminger & Claudia M. Klier. (2014) Perinatal Use of Aripiprazole. Journal of Clinical Psychopharmacology 34:5, pages 637-641.
Crossref
Crossref
Takeshi Suzuki, Kazuo Mihara, Akifumi Nakamura, Shoko Kagawa, Goyo Nagai, Kenji Nemoto & Tsuyoshi Kondo. (2014) Effects of Genetic Polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia. Therapeutic Drug Monitoring 36:5, pages 651-655.
Crossref
Crossref
Matt Shirley & Caroline M. Perry. (2014) Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia. Drugs 74:10, pages 1097-1110.
Crossref
Crossref
Takaaki Ishikawa, Takahiro Shinozaki & Kazutaka Shimoda. (2014) Rhabdomyolysis After the Administration of Clarithromycin in a Japanese Schizophrenic Patient Receiving Aripiprazole: A Possible Impact of CYP2D6 Genotype. Clinical Neuropsychopharmacology and Therapeutics 5:0, pages 18-22.
Crossref
Crossref
Ali Mokhtari. (2014)
Sensitive determination of aripiprazole using chemiluminescence reaction of tris(1,10-phenanthroline)ruthenium(
ii
) with acidic Ce(
iv
)
. Anal. Methods 6:24, pages 9588-9595.
Crossref
Crossref
Sergio De Filippis, Ilaria Cuomo, Luana Lionetto, Delfina Janiri, Maurizio Simmaco, Matteo Caloro, Simone De Persis, Gioia Piazzi, Alessio Simonetti, C Ludovica Telesforo, Antonio Sciarretta, Federica Caccia, Giovanna Gentile, Georgios D. Kotzalidis & Paolo Girardi. (2013) Intramuscular Aripiprazole in the Acute Management of Psychomotor Agitation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:6, pages 603-614.
Crossref
Crossref
Joseph K. Maddry, Klementyna Breyer, Kelly M. Cook & Kennon Heard. (2013) Monomorphic ventricular tachycardia after intentional citalopram overdose. The American Journal of Emergency Medicine 31:2, pages 447.e5-447.e8.
Crossref
Crossref
Goyo Nagai, Kazuo Mihara, Akifumi Nakamura, Takeshi Suzuki, Kenji Nemoto, Shoko Kagawa, Ikuya Ohta, Hajime Arakaki & Tsuyoshi Kondo. (2012)
Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of
dopamine
D
2 receptor
and
cytochrome
P
450 2
D
6
in Japanese patients with schizophrenia
. Psychiatry and Clinical Neurosciences 66:6, pages 518-524.
Crossref
Crossref
Renata Rizzo, Mariangela Gulisano & Paola Valeria Calì. (2012) Oculogyric crisis: a rare extrapyramidal side effect in the treatment of Tourette syndrome. European Child & Adolescent Psychiatry 21:10, pages 591-592.
Crossref
Crossref
Kenji Nemoto, Kazuo Mihara, Akifumi Nakamura, Goyo Nagai, Shoko Kagawa, Takeshi Suzuki & Tsuyoshi Kondo. (2012) Effects of Paroxetine on Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia. Therapeutic Drug Monitoring 34:2, pages 188-192.
Crossref
Crossref
Shih-Ku Lin, Chih-Ken Chen & Yu-Li Liu. (2011) Aripiprazole and Dehydroaripiprazole Plasma Concentrations and Clinical Responses in Patients With Schizophrenia. Journal of Clinical Psychopharmacology 31:6, pages 758-762.
Crossref
Crossref
Tanja Veselinović, Holger Schorn, Ingo Vernaleken, Katharina Schiffl, Christoph Hiemke, Gerald Zernig, Ruben Gur & Gerhard Gründer. (2011) Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology 218:4, pages 733-748.
Crossref
Crossref
Claire Chevreuil, Elisabeth Polard, Eric Lemonnier, Paul Guillemot & Danièle Bentué-Ferrer. (2011) Prescription de l’aripiprazole chez l’enfant et l’adolescent. Therapies 66:2, pages 123-130.
Crossref
Crossref
Stephan Leucht, Christoph U. Correll & John M. Kane. 2010. Schizophrenia. Schizophrenia
540
560
.
Magnhild Hendset, Espen Molden, Torill Bakko Enoksen, Helge Refsum & Monica Hermann. (2010) The Effect of Coadministration of Duloxetine on Steady-State Serum Concentration of Risperidone and Aripiprazole: A Study Based on Therapeutic Drug Monitoring Data. Therapeutic Drug Monitoring 32:6, pages 787-790.
Crossref
Crossref
Katrin M. Kirschbaum, Manfred Uhr, David Holthoewer, Christian Namendorf, Claus Pietrzik, Christoph Hiemke & Ulrich Schmitt. (2010) Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 59:6, pages 474-479.
Crossref
Crossref
Markus J. Schwarz, R. Musil, I. Spellmann, M. Opgen-Rhein, F. Jurgeleit, S. Sirch, S. Sterz, J. Zach & M. Riedel. 2010. Schizophrenie — Zukunftsperspektiven in Klinik und Forschung. Schizophrenie — Zukunftsperspektiven in Klinik und Forschung
229
241
.
Eva Choong, Serge Rudaz, Astrid Kottelat, Davy Guillarme, Jean-Luc Veuthey & Chin B. Eap. (2009) Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC–MS. Journal of Pharmaceutical and Biomedical Analysis 50:5, pages 1000-1008.
Crossref
Crossref
David Taylor, Carol Paton & Shitij Kapur. 2009. The Maudsley Prescribing Guidelines, Tenth Edition. The Maudsley Prescribing Guidelines, Tenth Edition
1
8
.
Leo Bastiaens. (2009) Pharmacotherapy of Bipolar I Disorder: Focus on Aripiprazole. Clinical Medicine. Therapeutics 1, pages CMT.S2238.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:1.
Crossref
Crossref
Milica Vranic, Fozia Ahmed, Susanne Hetty, Assel Sarsenbayeva, Vitor Ferreira, Giovanni Fanni, Ángela M. Valverde, Jan W. Eriksson & Maria J. Pereira. (2022) Molecular Insights into Divergent Effects of Second-Generation Antipsychotics on Human Adipocyte Metabolism. SSRN Electronic Journal.
Crossref
Crossref
Milica Vranic, Vitor Ferreira, Susanne Hetty, Assel Sarsenbayeva, Fozia Ahmed, Giovanni Fanni, Ángela M. Valverde, Jan W. Eriksson & Maria J. Pereira. (2022) Aripiprazole, But Not Olanzapine, Directly Inhibits Human Adipocyte Differentiation and Glucose Metabolism. SSRN Electronic Journal.
Crossref
Crossref